News | Peripheral Artery Disease (PAD) | June 16, 2020

Excellent 3-year Results in MIMICS-2 Study of the BioMimics 3D Vascular Stent 

Femoropopliteal stent showed 81 percent of patients did not need repeat revascularization

he 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent showed low rates of revascularization and compared very favorably to current standards of care.  The results were presented by Professor Thomas Zeller, M.D., University Heart Centre Freiburg, Bad Krozingen, Germany at the CX 2020 Live conference.   

June 16, 2020 — The 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent showed low rates of revascularization and compared very favorably to current standards of care.  The results were presented by Professor Thomas Zeller, M.D., University Heart Centre Freiburg, Bad Krozingen, Germany at the Charing Cross CX 2020 Live conference.   

Zeller announced in the first presentation of the 36 month results, that the freedom from target legion revascularization (TLR) at 3 years for the BioMimics 3D stent was 81 percent. This is comparable to the outcomes for drug-coated balloons (DCB), drug-eluting stents (DES) and the self-expanding Supera stent. The vendor said the positive results were achieved even with treating more challenging lesions and without the need for lesion preparation. A sub-analyses presented showed that the TLR 3-year outcome was independent of the presence of severe calcium, total occlusions and long lesions. 

MIMICS-2 is a prospective, single-arm, multi-centre clinical study to evaluate the safety and effectiveness of the BioMimics 3D Vascular Stent System in the treatment of patients with symptomatic atherosclerotic disease of the femoropopliteal artery. 

Conducted under an FDA Investigational Device Exemption (IDE) with concurrence of the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) under the FDA/PMDA Harmonization By Doing collaboration, MIMICS-2 enrolled 271 subjects undergoing femoropopliteal intervention across 43 investigational sites in U.S., Japan and Germany. Professor Zeller, along with Timothy Sullivan, M.D., Minneapolis, and Professor Masato Nakamura, Tokyo, Japan, is a co-Principal Investigator.

“These are reproducible, rigorous and high quality data from the U.S., Japan and Europe and we are delighted that the MIMICS-2 results reinforce those from our earlier MIMICS-RCT study in a larger, more challenging patient population," said Nick Yeo, Veryan’s CEO. "The outcomes are comparable to those reported for drug-eluting stents and drug-coated balloons and suggest that mobilizing natural swirling flow is an alternative anti-restenosis strategy to the use of antiproliferative drugs. 

The BioMimics 3D stent has a unique three-dimensional helical shape, designed to impart natural curvature to the diseased femoropopliteal artery, promoting swirling flow and elevating wall shear, which has a protective effect on the endothelium.[1] The helical shape of the BioMimics 3D stent is also designed to facilitate shortening of the stented segment during knee flexion and mitigate the risk of stented segment compression causing localised strains that in a straight stent may lead to stent fracture and chronic vascular injury.[2,3] 

For more information: www.veryanmed.com 

References:

1. Zeller T. - Oral Presentation VIVA 2014 
2. BH Smouse et al. Biomechanical Forces in the Femoropopliteal Arterial Segment Endovasc. Today, vol 4, no. 6, pp. 60-66, 2005. 
3. Scheinert D et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005;45:312-5 doi:10.1016/j.jacc.2004.11.026 

 


Related Content

News | Cardiovascular Clinical Studies

May 18, 2024 — Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ...

Home May 18, 2024
Home
News | Cardiovascular Clinical Studies

May 17, 2024 — Royal Philips, a global leader in health technology, is presenting new retrospective study results ...

Home May 17, 2024
Home
News | Cardiovascular Clinical Studies

May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aortic valve in the ...

Home May 15, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 14, 2024 — An ambitious, nationwide clinical trial led by UVA Health’s Karen Johnston, MD, has provided doctors with ...

Home May 14, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms ...

Home May 13, 2024
Home
News | Cardiovascular Clinical Studies

May 13, 2024 — Even though mortality and hospitalization rates have improved, the quality of life for those living with ...

Home May 13, 2024
Home
News | Cardiovascular Clinical Studies

May 10, 2024 — Scientists from Immanuel Kant Baltic Federal University proved that Raman spectroscopy, a method by which ...

Home May 10, 2024
Home
Subscribe Now